Arcutis Biotherapeutics (ARQT) Set to Announce Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.08). The business had revenue of $13.53 million during the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative return on equity of 294.85%. During the same quarter last year, the firm earned ($1.18) EPS. On average, analysts expect Arcutis Biotherapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Down 0.9 %

Shares of ARQT stock traded down $0.07 during trading hours on Tuesday, hitting $7.88. 1,644,835 shares of the company were exchanged, compared to its average volume of 4,413,921. Arcutis Biotherapeutics has a 1 year low of $1.76 and a 1 year high of $15.12. The firm has a fifty day moving average of $9.98 and a 200 day moving average of $6.04. The firm has a market cap of $910.38 million, a PE ratio of -2.01 and a beta of 1.18. The company has a quick ratio of 6.80, a current ratio of 7.08 and a debt-to-equity ratio of 2.28.

Insider Activity

In related news, insider Masaru Matsuda sold 3,760 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $11.12, for a total transaction of $41,811.20. Following the transaction, the insider now directly owns 190,424 shares of the company's stock, valued at approximately $2,117,514.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.70% of the company's stock.

Wall Street Analyst Weigh In

ARQT has been the subject of several research reports. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Arcutis Biotherapeutics in a research note on Friday, April 12th. Mizuho restated a "buy" rating and issued a $16.00 price objective (up from $8.00) on shares of Arcutis Biotherapeutics in a report on Friday, February 23rd. Finally, The Goldman Sachs Group lifted their price objective on Arcutis Biotherapeutics from $6.00 to $11.00 and gave the company a "neutral" rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $26.56.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.